ArticleAntimicrobial agents and chemotherapy1996
Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide.
Article in Antimicrobial agents and chemotherapy, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023Review
- Liposomal amphotericin B-the future.The Journal of antimicrobial chemotherapy · 2022Article
- Article
- It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.Frontiers in microbiology · 2012Article
- Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei Infections.PLoS pathogens · 2012Article
- Chemokine receptor 2-mediated accumulation of fungicidal exudate macrophages in mice that clear cryptococcal lung infection.The American journal of pathology · 2011Article
- Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects.The Journal of membrane biology · 2010Review
- Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2008Review
- Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection.Antimicrobial agents and chemotherapy · 2005Article
- Reactive oxygen intermediates, nitrite and IFN-gamma in Indian visceral leishmaniasis.Clinical and experimental immunology · 2001Article
- Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.Antimicrobial agents and chemotherapy · 2001Article
- Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations.Antimicrobial agents and chemotherapy · 1999Article
- Different susceptibilities of yeasts and conidia of Penicillium marneffei to nitric oxide (NO)-mediated fungicidal activity of murine macrophages.Clinical and experimental immunology · 1998Article
- KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis.Antimicrobial agents and chemotherapy · 1998Article
- Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.Antimicrobial agents and chemotherapy · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amphotericin B (AmB) is a classical antifungal drug and one of the most effective antifungal drugs for the treatment of systemic fungal infection. It is also known to have various immunomodulating activities other than its direct antifungal effect. In the present study, we demonstrated that AmB augmented gamma interferon (IFN-gamma)-induced killing potentials of murine peritoneal macrophages against Cryptococcus neoformans in a dose-dependent manner. This effect was strongly blocked by NG-monomethyl-L-arginine, a competitive inhibitor of nitric oxide (NO) synthesis. In addition, AmB markedly augmented macrophage NO production induced by IFN-gamma with a dose-response curve similar to that seen with its effect on the anticryptococcal activity. These effects were partially mediated by either tumor necrosis factor alpha or interleukin-1, because AmB enhanced IFN-gamma-induced production of these cytokines by macrophages and their specific antibodies partially inhibited the AmB-induced enhancement of NO generation when they were used separately. Our results indicate that AmB induces the production of tumor necrosis factor alpha and IL-1 by macrophages and augments their anticryptococcal activity through triggering the NO-dependent pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.